The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research

Affiliations

¹ Division of Hematology/Oncology, Orphan Disease Center, & Leonard Davis Institute for Health Economics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: davidfa@mail.med.upenn.edu.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
³ Faculty of Medicine, University of British Columbia, Vancouver V6T 1Z1, Canada.
⁴ Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Comment

David C Fajgenbaum et al. Lancet Haematol. 2016 Apr.

. 2016 Apr;3(4):e150-2.

doi: 10.1016/S2352-3026(16)00007-7. Epub 2016 Mar 17.

¹ Division of Hematology/Oncology, Orphan Disease Center, & Leonard Davis Institute for Health Economics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: davidfa@mail.med.upenn.edu.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
³ Faculty of Medicine, University of British Columbia, Vancouver V6T 1Z1, Canada.
⁴ Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

No abstract available

Comment on

Idiopathic multicentric Castleman's disease: a systematic literature review.
Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, Krymskaya VP, Kelleher D, Rubenstein AH, Fajgenbaum DC. Liu AY, et al. Lancet Haematol. 2016 Apr;3(4):e163-75. doi: 10.1016/S2352-3026(16)00006-5. Epub 2016 Mar 17. Lancet Haematol. 2016. PMID: 27063975